Stayble Therapeutics
0.17 SEK
-3.35 %
Less than 1K followers
STABL
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Stayble Therapeutics
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| growth-% | |||||||
| EBITDA | -6.9 | -14.9 | -12.1 | -24.8 | -24.0 | -12.8 | - |
| EBIT | -6.9 | -14.9 | -12.1 | -24.8 | -24.0 | -12.8 | -6.9 |
| Profit before taxes | -7.4 | -15.5 | -12.1 | -24.5 | -23.7 | -12.4 | -6.9 |
| Net income | -7.4 | -15.5 | -12.1 | -24.5 | -23.7 | -12.4 | -6.9 |
| EPS | -0.83 | -1.74 | -0.85 | -1.72 | -0.92 | -0.33 | -0.12 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | |||||||
| EBIT-% | |||||||
| ROE | 2,511.2 % | -99.6 % | -30.4 % | -160.5 % | -143.8 % | -180.8 % | -100.1 % |
| ROI | -76.2 % | -86.1 % | -27.7 % | -128.1 % | -109.4 % | -134.1 % | -80.4 % |